Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

This study aims to validate a possible diagnostic test for bile acid diarrhoea prospectively compared to the SeHCAT scintigraphy. Fasting participants are given a standard meal and 1,250 mg chenodeoxycholic acid. The investigators measure fasting FGF19, bile acids species including 7-alpha-CHO and serial blood samples after the stimulation.

Inclusion Criteria:

- Consecutive patients referred for SeHCAT

Exclusion Criteria:

• Treatment with sequestrants within one week before the SeHCAT.
• Treatment with any constipants/laxatives one day before the SeHCAT, with the exception of opioids, if the dosis has been stable in the prior 2 weeks.
• Pregnancy, screening by pregnancy test before inclusion.
• Breastfeeding women.
• Small bowel resection, including right sided hemicolectomy.
• Any ongoing treatment for inflammatory bowel disease with systemic steroids (i.e. budesonide or prednisone) or treatment in the prior 4 weeks.
• Allergies to constituents of Xenbilox: (chenodeoxycholic acid, cornflour, magnesium stearate, highly dispersed silica, gelatine, sodium dodecylsulphate, titanium dioxide (E171), quinolone yellow (E104), erythrosine (E127)
• Chronic or acute cholecystitis.
• Liver cirrhosis,
• Obstructed bile flow causing jaundice or elevated p-bilirubin (> 1,5 UNL).
• Known disability in gall bladder contractility.
• Bile duct atresia.
• Frequent gallstone attacks (>2/month).